Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EPI-506 |
Synonyms | |
Therapy Description |
EPI-506 (ralaniten acetate), the prodrug for EPI-002, is a small molecule that inhibits the N-terminal domain of the androgen receptor (AR), potentially resulting in decreased AR signaling, including in the context of mutant AR (PMID: 27628492, PMID: 27140928). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EPI-506 | Ralaniten acetate | Hormone - Anti-androgens 54 | EPI-506 (ralaniten acetate), the prodrug for EPI-002, is a small molecule that inhibits the N-terminal domain of the androgen receptor (AR), potentially resulting in decreased AR signaling, including in the context of mutant AR (PMID: 27628492, PMID: 27140928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02606123 | Phase Ib/II | EPI-506 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | Terminated | USA | CAN | 0 |